Changes of CD3bright T lymphocytes in patients with hepatocellular carcinoma before and after recurrence

doi:10.3969/j.issn.1673-8640.2020.03.005

Abstract

Abstract:

Objective To investigate the changes of CD3^bright T lymphocytes in patients with hepatocellular carcinoma（HCC） before and after recurrence. Methods A total of 69 patients with HCC,including 52 cases of recurrence within 5 years and 17 cases without recurrence,were enrolled. By flow cytometry,the proportions of CD3⁺T cells,CD4⁺T cells,CD8⁺T cells and CD3^bright T cells in total T cells（CD3%,CD4%,CD8% and CD3^bright%） were determined,and the CD4/CD8 ratio was calculated. Alpha-fetoprotein（AFP） was determined as well. Pearson correlation analysis was used to evaluate the correlation of CD3^bright% with other indicators. Logistic regression analysis was used to evaluate the indicators for the prediction of HCC recurrence. By receiver operating characteristic（ROC） curve analysis,the roles of the indicators for the judgment of HCC recurrence were evaluated. Results The levels of AFP,CD4% and CD8% were higher（P<0.01）,and CD3^bright% was lower in patients with recurrence within 5 years than those without recurrence（P<0.01）. There was no statistical significance for CD3% and CD4/CD8 ratio between the 2 groups（P>0.05）. The level of AFP after recurrence was higher than that after operation（P<0.01）,CD3^bright% was decreased after recurrence（P=0.04）,and there was no statistical significance for the other indicators（P>0.05）. AFP and CD3^bright% were related with HCC recurrence independently [odds ratios（OR） were 1.012 and 0.841,95% confidence intervals（CI） were 1.001-1.023 and 0.783-0.902 ]. Conclusions Decreased CD3^brightT lymphocyte is related with poor prognosis and high recurrence rate.

Key words: CD3^bright T lymphocyte, CD4, CD8, Alpha-fetoprotein, Hepatocellular carcinoma, Recurrence

CLC Number:

R446.1

JIN Fangfang, JIN Zizheng, LIU Ning, LOU Jinli. Changes of CD3^bright T lymphocytes in patients with hepatocellular carcinoma before and after recurrence[J]. Laboratory Medicine, 2020, 35(3): 209-213.

Figures/Tables 4

References 16

[1]	CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[2]	TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2): 87-108.
[3]	POMPILI M,SAVIANO A,DE MATTHAEIS N,et al.Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3cm. Results of a multicenter Italian survey[J]. J Hepatol,2013,59(1): 89-97.
[4]	HEIMBACH J K,KULIK L M,FINN R S,et al.AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology,2017,67(1):358-380.
[5]	LAMBERT C,GENIN C.CD3 bright lymphocyte population reveal gammadelta T cells[J]. Cytometry B Clin Cytom,2004,61(1):45-53.
[6]	SONG B,ZHEN S,MENG F.T cell inflammation profile after surgical resection may predict tumor recurrence in HBV-related hepatocellular carcinoma[J]. Int Immunopharmacol,2016,41:35-41.
[7]	HUANG Y,WANG F M,WANG T,et al.Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients[J]. Digestion,2012,86(4):329-337.
[8]	CHEN X,DU Y,HU Q,et al.Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4[J]. Pathol Res Pract,2016,213(3):245.
[9]	AGGARWAL N,FISCHER J,SWERDLOW S H,et al.Splenic lymphoid subsets with less well-recognized phenotypes mimic aberrant antigen expression[J]. Am J Clin Pathol,2013,140(6):787-794.
[10]	PAGET C,CHOW M T,GHERARDIN N A,et al.CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells[J]. Immunol Cell Biol,2015,93(2):198-212.
[11]	MCKENZIE D R,KARA E E,BASTOW C R,et al.IL-17-producing γδ T cells switch migratory patterns between resting and activated states[J]. Nat Commun,2017,8:15632.
[12]	ZHAO Y,NIU C,CUI J.Gamma-delta(γδ) T cells:friend or foe in cancer development?[J]. J Transl Med,2018,16(1):122.
[13]	YOKOBORI N,SCHIERLOH P,GEFFNER L,et al.CD3 expression distinguishes two gammadelta T cell receptor subsets with different phenotype and effector function in tuberculous pleurisy[J]. Clin Exp Immunol,2009,157(3):385-394.
[14]	PATIN E C,SOULAR D,FLEURY S,et al.Type Ⅰ IFN receptor signaling controls IL-7-dependent accumulation and activity of protumoral IL17A-producing γδT cells in breast cancer[J]. Cancer Res,2018,78(1):195-204.
[15]	CHEN C L,WANG Y,HUANG C Y,et al.IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma[J]. Oncoimmunology,2017,7(1):e1373234.
[16]	BAO Y,GUO L,MO J.Characterization of γδ T cells in patients with non-small cell lung cancer[J]. Oncol Lett,2017,14(1):1133-1140.

组别	例数	AFP/（ng/mL）	CD3^bright%/%	CD3%/%	CD4%/%	CD8%/%	CD4/CD8比值
复发组	52	3.55（2.15~10.32）	2.46（1.67~3.36）	69.28（61.44~75.75）	35.93（30.83~42.22）	26.65（21.65~31.51）	1.39（1.03~1.76）
未复发组	17	2.46（1.73~3.68）	6.50（3.58~10.23）	65.76（57.06~72.16）	31.60（27.98~34.82）	24.40（16.61~29.84）	1.33（1.33~1.84）
U值		2 346.50	854.50	2 794.50	2 311.00	2 573.50	3 236.00
P值		<0.01	<0.01	0.06	<0.01	<0.01	0.88

组别	例数	AFP/（ng/mL）	CD3^bright%/%	CD3%/%	CD4%/%	CD8%/%	CD4/CD8比值
复发组	52	3.55（2.15~10.32）	2.46（1.67~3.36）	69.28（61.44~75.75）	35.93（30.83~42.22）	26.65（21.65~31.51）	1.39（1.03~1.76）
未复发组	17	2.46（1.73~3.68）	6.50（3.58~10.23）	65.76（57.06~72.16）	31.60（27.98~34.82）	24.40（16.61~29.84）	1.33（1.33~1.84）
U值		2 346.50	854.50	2 794.50	2 311.00	2 573.50	3 236.00
P值		<0.01	<0.01	0.06	<0.01	<0.01	0.88

项目	例数	AFP/（ng/mL）	CD3^bright%/%	CD3%/%	CD4%/%	CD8%/%	CD4/CD8比值
术后	52	3.27（2.04~5.69）	2.67（2.07~3.32）	68.43（60.80~75.78）	34.35（30.00~38.70）	27.39（22.06~35.61）	1.39（0.95~1.73）
复发时	17	16.85 （4.40~22.60）	1.93（1.33~3.47）	69.77（62.03~75.86）	37.62（33.57~43.44）	27.75（20.52~30.99）	1.59（1.25~1.92）
U值		886.50	901.00	1 173.00	917.00	935.50	861.00
P值		0.03	0.04	0.87	0.05	0.07	0.06

项目	例数	AFP/（ng/mL）	CD3^bright%/%	CD3%/%	CD4%/%	CD8%/%	CD4/CD8比值
术后	52	3.27（2.04~5.69）	2.67（2.07~3.32）	68.43（60.80~75.78）	34.35（30.00~38.70）	27.39（22.06~35.61）	1.39（0.95~1.73）
复发时	17	16.85 （4.40~22.60）	1.93（1.33~3.47）	69.77（62.03~75.86）	37.62（33.57~43.44）	27.75（20.52~30.99）	1.59（1.25~1.92）
U值		886.50	901.00	1 173.00	917.00	935.50	861.00
P值		0.03	0.04	0.87	0.05	0.07	0.06

项目	单变量		多变量
项目	OR值（95%CI）	P值	OR值（95%CI）	P值
AFP	1.012（1.001~1.023）	0.03	1.012（1.001~1.023）	0.03
CD3^bright%	0.841（0.785~0.900）	<0.01	0.841（0.783~0.902）	<0.01
CD3%	1.033（1.006~1.060）	0.02	1.029（0.996~1.063）	0.09
CD4%	1.030（1.002~1.059）	0.12
CD8%	1.048（1.016~1.081）	<0.01	1.032（0.994~1.072）	0.1
CD4/CD8比值	0.805（0.605~1.071）	0.14